Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

This publication has 30 references indexed in Scilit:

• Complete Androgen Blockade versus Chemical Castration in Advanced Prostatic Cancer: Analysis of an Italian Multicentre Study
  Urologia Internationalis, 1998
• Maximal Androgen Blockade: Final Analysis of EORTC Phase III Trial 30853
  European Urology, 1998
• Maximum Androgen Blockade Using LHRH Agonist Buserelin in Combination with Short-Term (Two Weeks) or Long-Term (Continuous) Cyproterone Acetate Is Not Superior to Standard Androgen Deprivation in the Treatment of Advanced Prostate Cancer
  European Urology, 1998
• Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate — an Australian multicentre trial
  British Journal of Urology, 1996
• A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate
  European Journal Of Cancer, 1995
• Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer
  European Journal Of Cancer, 1993
• A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
  New England Journal of Medicine, 1989
• Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)
  New England Journal of Medicine, 1989
• 10-Jahres-Ergebnisse einer randomisierten Prospektivstudie beim metastasierten Prostatakarzinom
  Aktuelle Urologie, 1987
• Orchiectomy Combined with Cyproterone Acetate or Prednisone in the Treatment of Advanced Prostatic Carcinoma
  Scandinavian Journal of Urology and Nephrology, 1982